Skip to content

Anne K. Schlag

5 papers in the library · 516 citations · publishing 2017-2024

Papers

Sort Most recent Most cited

Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.

Psychological Medicine December 1, 2023 Paul McCrone, Henry Fisher, Clare Knight et al. 34 citations

There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-effectiveness of psilocybin-assisted psychotherapy (PAP) with conventional medication, cognitive behavioural therapy (CBT), and the combination of conventional medication and CBT. A decision model simulated patient events (response, remission, and...

Risks and adverse events associated with the use of psychedelics

Psychedelics as Psychiatric Medications March 1, 2023 Joanna C. Neill, Mohammed Shahid, Rosalind Gittins et al.

Abstract Improved understanding of the potential risks and adverse effects of psychedelics is essential before psychedelic-assisted therapy is adopted into mainstream medicine. In spite of numerous recent clinical trials, gaps in knowledge remain. A comprehensive analysis of human receptor pharmacology is required to inform clinical dosing strategies and improve the understanding of drug-drug...

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.

J Psychopharmacol February 2, 2022 Anne K. Schlag, Jacob S. Aday, Iram Salam et al. 319 citations

BACKGROUND: Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a controversial issue among the public and politicians, tainted by previous stigmatisation and perceptions of risk and danger. OBJECTIVE: This narrative review examines the evidence for potential harms of the classic psychedelics by separating...

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.

Lancet Psychiatry April 5, 2017 Ilina Singh, Celia J. A. Morgan, Valerie H. Curran et al. 158 citations

We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The analysis of ethical considerations is contextualised in an overview of the evidence for ketamine use in depression, and a review of the drug's safety profile. We find that, based on current evidence, ketamine use for severe, treatment-resistant depression does...